| Name | Title | Contact Details |
|---|---|---|
Mark Fulmer |
Director, Global R&D Biomaterials Bone Substitutes | Profile |
Bob Donohue |
CFO | Profile |
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Crosscart Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
FLX Bio, Inc. is a biotechnology company focused on the discovery and development of novel therapies that will improve and prolong the lives of people with cancer. The company is targeting key cancer pathways with its clinical-stage program, FLX925, and building a pipeline of immuno-oncology oral medicines designed to activate a patient`s own immune system to eradicate cancer.
Indevus Pharmaceuticals Inc. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.